chartexchange

Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?

The Motley Fool | Oct 17, 2026 9:00 PM EDT

Cathie Wood, the CEO and founder of Ark Investment Management, owns, through her various Ark ETFs, $220.4 million in Beam Therapeutics (NASDAQ: BEAM) shares. It is a healthcare company that focuses on gene editing to develop precision medicines. She has owned shares in Beam through her various Ark Technology ETFs for more than five years. On Oct. 12 and Oct. 13, she spent an additional $2.8 million on Beam shares for her Ark Genomic Revolution (NYSEMKT: ARKG) fund. . The company is a long way from profitability, but thanks to its potential, it is a worthwhile biotech stock to buy if you're willing to handle some volatility and risk. Continue reading

Read original article